|Bid||147.48 x 1100|
|Ask||147.55 x 800|
|Day's Range||145.98 - 147.76|
|52 Week Range||134.25 - 178.86|
|PE Ratio (TTM)||458.23|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||1.36 (0.91%)|
|1y Target Est||171.60|
McKesson Corp. cut Chief Executive Officer John Hammergren’s pay by about 10 percent following a shareholder revolt spurred by claims about the health-care firm’s alleged role in the nation’s opioid crisis. The International Brotherhood of Teamsters led a vote-no campaign in 2017 against the firm’s executive pay plan after accusing the drug distributor of aggravating the opioid epidemic. “Our compensation committee undertook a robust process to review the company’s executive compensation structure, taking into account feedback from our shareholders gathered during an extensive outreach effort,” Ed Mueller, McKesson’s lead independent director, said in an emailed statement.
This includes claims from Kentucky Attorney General Andy Beshear that the company took part in “unlawful business practices.” while doing so. According to Beshear, Walgreens was open to filling suspicious amounts of opioid orders in the state and helped fuel the crisis. The lawsuit against Walgreens is seeking several changes.
ISLANDIA, N.Y., June 12, 2018 /PRNewswire/ -- Pharmapacks, a leading e-commerce company with a proprietary technology platform that empowers brands to reach millions of consumers with a complete and cost-effective logistics, fulfillment, marketing and sales solution, today announced it has raised $32.5 million by selling a minority stake at an undisclosed valuation. The strategic round was led by multinational CPG company RB (RB.L) with additional investments from McKesson Ventures, Sealed Air (SEE) and The Emerson Group. Pharmapacks sells both direct-to-consumer through leading online marketplaces including Amazon, Walmart.com, and eBay among others, as well as on Pharmapacks.com.
The McKesson Corp. will close its RxCrossroads "discrete operating unit" at 6251 Chancellor Drive in Suite 101. The company informed the Florida Department of Economic Opportunity on May 23 that it plans to lay off 126 workers from July 31-Sept. 28. McKesson Corp. did not disclose why it is closing its Orlando location.
The following is a collection of this week’s deal closings for transactions involving private-equity firms and portfolio companies.
McKesson Corporation , a global leader in healthcare supply chain management solutions, announced today that it has completed the previously announced acquisition of Medical Specialties Distributors.
Drugstore stocks have been under pressure in the past year due to fears of Amazon (AMZN) entering the pharma space, President Trump’s drug pricing policy change, and the ongoing consolidation wave in the industry.
McKesson Corporation today announced that Britt Vitalone, executive vice president and chief financial officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA at 2:00 p.m.
Among the companies with shares expected to trade actively in Thursday's session are Apple, General Motors, General Electric, 21st Century Fox, Qualcomm and Best Buy.
The electronics retailer earned an adjusted 82 cents per share for the first quarter , 8 cents a share above estimates, with revenue also exceeding forecasts. Best Buy reported a comparable store sales increase of 7.1 percent, well above the consensus Thomson Reuters forecast of a 3.0 percent increase. Medtronic MDT – The medical device maker's quarterly numbers came in 3 cents above estimates at an adjusted $1.42 per share, with revenue also above Street forecasts.
On a per-share basis, the San Francisco-based company said it had a loss of $5.58. Earnings, adjusted for one-time gains and costs, came to $3.49 per share. The results fell short of Wall Street expectations. ...
Medical supplies distributor McKesson Corp. said Thursday it had a net loss of $1.146 billion, or $5.58 a share, in its fiscal fourth quarter to March 31, after a profit of $3.588 billion, or $16.76 a share, in the year-earlier period. The loss was driven primarily by non-cash goodwill and long-lived asset impairment charges in the company's European and Canadian retail businesses, which were partially offset by benefits related to the December tax revamp.
McKesson Corporation today reported that revenues for the fourth quarter ended March 31, 2018, were $51.6 billion, up 6% compared to $48.7 billion a year ago. On a constant currency basis, revenues increased 4% over the prior year.
Retail earnings will continue on Thursday with Best Buy and The Gap reporting results as volumes remain light ahead of the holiday weekend in the U.S.
The FDA released a list of drugmakers it said are getting in the way of generic drug development. Stocks of pharmacy benefit managers and biotech companies still outperformed the market. The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
McKesson's (MCK) Q4 results likely to be driven by core segmental performance; solid view and new growth initiatives buoy optimism.